Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment
Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based...
Apollomics
Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China
US-based biotech Apollomics Inc., (NASDAQ: APLM) has announced that its Chinese partner, Beijing Avistone Pharmaceuticals...
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...
Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing
Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...